• AstraZeneca average return on tangible equity for 2023 was -25.75, a 733.33% increase from 2022.
• AstraZeneca average return on tangible equity for 2022 was -3.09, a 76.39% increase from 2021.
• AstraZeneca average return on tangible equity for 2021 was -13.09, a 2.83% decline from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.